

**LifeSci Biotechnology Clinical Trials Index****Removal of Component(s) – AVXS****5/9/2018**

Effective at the market close on Monday, May 14, 2018, **AVXS** will be removed from the **LifeSci Biotechnology Clinical Trials Index** and its value will be redistributed to the remaining index components based on their weights.

- On 4/9/2018, AveXis (AVXS) announced that it will be acquired by Novartis AG for \$218 per share in cash.